Esperion, Cleveland Clinic Collaborate

6/14/10

Esperion Therapeutics, a biopharmaceutical company based in Ann Arbor, MI, has signed an agreement with the Cleveland Clinic to advance research targeting new HDL therapies to treat cardiovascular disease. “When Esperion was first founded, we collaborated with Cleveland Clinic in a research effort that showed for the first time that HDL can reverse atherosclerosis in acute coronary patients,” Roger Newton, Esperion president and CEO, says in a prepared statement. “When we re-established Esperion in 2008, our goal was to continue this research tradition.” Esperion is developing therapies to treat cardio-metabolic disease including therapies based on HDL, the body’s “good” cholesterol, which has been shown to play an important role in lipid management.

By posting a comment, you agree to our terms and conditions.